Allogene Therapeutics, Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | 2.9M | 3.1M | 31.2M | 40.2M | 3.1M | 3.2M | 44.7M | 50.4M |
| Gross Profit | -2.9M | -3.1M | -31.2M | -40.2M | -3.1M | -3.2M | -44.7M | -50.4M |
| R&D Expenses | 29.1M | 28.6M | 31.2M | 40.2M | 50.2M | 45.0M | 44.7M | 50.4M |
| Operating Expenses | 43.2M | 39.3M | 13.7M | 16.7M | 62.1M | 57.3M | 27.1M | 21.1M |
| Operating Income | -46.1M | -42.4M | -44.9M | -56.8M | -65.2M | -60.5M | -71.8M | -71.4M |
| Other Income / Gains | 3.5M | 3.6M | 3.5M | 5.9M | 5.5M | 994K | 5.5M | 5.1M |
| Net Income | -42.6M | -38.8M | -41.4M | -50.9M | -59.7M | -59.9M | -66.3M | -66.4M |
| EPS (Diluted) | -0.18 | -0.17 | -0.19 | -0.23 | -0.28 | -0.28 | -0.32 | -0.35 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General And Administrative Expenses | 14.1M | 13.8M | 13.7M | 14.3M | 15.0M | 15.5M | 16.3M | 16.1M |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 14.1M | 13.8M | 13.7M | 14.3M | 15.0M | 15.5M | 16.3M | 16.1M |
| Other Expenses | 0 | -3.1M | -31.2M | -37.8M | -3.1M | -3.2M | -34.0M | -45.4M |
| Cost And Expenses | 46.1M | 42.4M | 44.9M | 56.8M | 65.2M | 60.5M | 71.8M | 71.4M |
| Interest Income | 3.6M | 3.7M | 3.9M | 6.2M | 5.5M | 3.0M | 6.7M | 5.0M |
| Interest Expense | 300K | 313K | 344K | 268K | 150K | 81K | 100K | 0 |
| Depreciation And Amortization | 2.9M | 3.1M | 3.1M | 3.1M | 3.1M | 3.2M | 3.2M | 3.6M |
| Ebitda | -39.4M | -35.4M | -38.0M | -47.6M | -56.5M | -56.2M | -63.0M | -62.7M |
| Ebitdaratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income Ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Before Tax | -42.6M | -38.8M | -41.4M | -50.9M | -59.7M | -59.5M | -66.3M | -66.4M |
| Income Before Tax Ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 443K | 0 | 0 |
| Net Income Ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Epsdiluted | -0.18 | -0.17 | -0.19 | -0.23 | -0.28 | -0.28 | -0.32 | -0.35 |
| Weighted Average Shs Out | 240.3M | 220.6M | 222.0M | 218.9M | 215.4M | 210.6M | 209.2M | 190.0M |
| Weighted Average Shs Out Dil | 240.3M | 220.6M | 222.0M | 218.9M | 215.4M | 210.6M | 209.2M | 190.0M |